17α-Dihydroequilin

Chemical compound

File:17α Dihydroequilin.svg

Chemical structure of 17α-Dihydroequilin

17α-Dihydroequilin is a naturally occurring estrogen and a metabolite of equilin, which is one of the primary estrogens found in conjugated equine estrogens (CEEs). CEEs are used in hormone replacement therapy for menopausal symptoms.

Chemical Structure and Properties

17α-Dihydroequilin is a steroidal estrogen with the chemical formula C18H22O2. It is characterized by its estrane core structure, which is typical of estrogens. The compound is a derivative of equilin, differing by the reduction of the 17-keto group to a hydroxyl group, which is reflected in its name "dihydro".

Biological Activity

As an estrogen, 17α-Dihydroequilin binds to and activates the estrogen receptor, which is a nuclear receptor that regulates the expression of genes involved in the development and maintenance of female reproductive tissues, as well as other physiological processes. The binding of 17α-Dihydroequilin to the estrogen receptor leads to the transcription of estrogen-responsive genes, which can influence a variety of biological functions.

Pharmacokinetics

In the body, 17α-Dihydroequilin is metabolized primarily in the liver. It is part of the complex mixture of estrogens present in CEEs, which are derived from the urine of pregnant mares. The pharmacokinetics of 17α-Dihydroequilin, like other components of CEEs, involves absorption, distribution, metabolism, and excretion processes that are typical of steroid hormones.

Clinical Use

17α-Dihydroequilin is not used as a standalone medication but is a component of CEEs, which are prescribed for the treatment of menopausal symptoms such as hot flashes, vaginal atrophy, and osteoporosis prevention. CEEs are one of the most commonly used forms of estrogen therapy in postmenopausal women.

Safety and Side Effects

The use of CEEs, including 17α-Dihydroequilin, is associated with certain risks and side effects. These may include an increased risk of breast cancer, endometrial cancer, thromboembolism, and cardiovascular disease. Patients are advised to discuss the risks and benefits of hormone replacement therapy with their healthcare provider.

Related Pages

• Estrogen
• Hormone replacement therapy
• Conjugated equine estrogens
• Menopause